title: Will targeting Chk1 have a role in the future of cancer therapy?
authors.affiliation: Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.
authors.forename: Nandini
authors.initials: N
authors.lastname: Sakurikar
authors.affiliation: Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH alan.r.eastman@dartmouth.edu.
authors.forename: Alan
authors.initials: A
authors.lastname: Eastman
mesh_terms: D000071877:Checkpoint Kinase 1; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D011494:Protein Kinases / Q000378:metabolism*; D011720:Pyrazoles / Q000008:administration & dosage* / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000627:therapeutic use*; D000093542:Gemcitabine
chemical_list: C559815:MK-8776; D011720:Pyrazoles; D011743:Pyrimidines; D003841:Deoxycytidine; D011494:Protein Kinases; C000605867:CHEK1 protein, human; D000071877:Checkpoint Kinase 1; D000093542:Gemcitabine